US EditionJelloX Research Collaborations Further Demonstrate Promise of 3D Pathology
- On March 27, 2025, JelloX Biotech Inc., a startup based in Hsinchu, Taiwan, announced a collaboration with the National Cancer Center Japan, including EPOC and the National Cancer Center Hospital East, to conduct a study on Japanese colorectal and esophageal cancer patients.
- This collaboration builds on JelloX's focus on advancing cancer pathology through 3D digital imaging and AI technology, and follows a 2024 partnership with a major US research institution, as well as plans to establish central laboratories in both Arizona and Tokyo.
- The study in Japan will focus on 3D analysis of the tumor microenvironment in esophageal cancer patients undergoing neoadjuvant chemotherapy and aims to validate a recent Taiwan-based clinical trial conducted with TMUH that applied JelloX's 3D pathology methods to colonoscopy specimens.
- JelloX CEO Dr. Yen-Yin Lin stated, "Backed by growing empirical data, the case for implementing 3D pathology in oncology is building" and emphasized that the technology's greater sensitivity enables precision for matching patients to the right treatments, ultimately improving treatment and quality of life.
- The expected outcomes of these collaborations include insights into drug development, predictive modeling of chemotherapy efficacy, and the potential for improved early detection and treatment of colorectal cancer, which is often asymptomatic in early stages, as well as regulatory approval in Japan and broader commercial deployment of JelloX's 3D pathology technology.
Insights by Ground AI
Does this summary seem wrong?
31 Articles
31 Articles
All
Left
2
Center
15
Right
Napa Valley Register+30 Reposted by 30 other sources
JelloX Research Collaborations Further Demonstrate Promise of 3D Pathology
Results of a Taiwan-based study are expected to be validated in a new collaboration with a major Japanese medical institution, assessing the higher sensitivity of 3D pathology over conventional sampling techniques across populations and medical systems.
Coverage Details
Total News Sources31
Leaning Left2Leaning Right0Center15Last UpdatedBias Distribution88% Center
Bias Distribution
- 88% of the sources are Center
88% Center
12%
C 88%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
